📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti-PLA2 R positive primary membranous nephropathy. (2018)

First Author: Hamilton P

Attributed to: The University of Manchester (UoM) bid for phase III of MRC Confidence in Concept funding funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/jca.21599

PubMed Identifier: 29094388

Publication URI: http://europepmc.org/abstract/MED/29094388

Type: Journal Article/Review

Volume: 33

Parent Publication: Journal of clinical apheresis

Issue: 3

ISSN: 0733-2459